Yüklüyor......
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients
In chronic myeloid leukemia (CML) and Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) patients who fail imatinib treatment, BCR-ABL1 mutation profiling by Sanger sequencing (SS) is recommended before changing therapy since detection of specific mutations influences second-generation t...
Kaydedildi:
| Yayımlandı: | Oncotarget |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Impact Journals LLC
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5008338/ https://ncbi.nlm.nih.gov/pubmed/26980736 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8010 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|